Top Biopharma Deal May 2021: Agenus – BMS for AGEN-1777 Bispecific Anti-TIGIT Antibody for Non-Small Cell Lung Cancer

by | Jun 5, 2021

Top Biopharma Partnership by Upfront Cash and Equity

May 2021

Agenus development and commercialization deal with BMS for AGEN-1777

Announced: May. 18, 2021

Total Deal Value: $1,560M

Upfront Cash: $200M

Upfront Equity: n/a

Option Payments: n/a

Milestones: $1,360M Dev., Reg., Sales

Royalties: Tiered Double-Digit

The Asset:

Preclinical bispecific anti-TIGIT antibody AGEN-1777 and an undisclosed target immuno-oncology therapy, including non-small cell lung cancer (NSCLC).

Deal Structure:

Development and Commercial License

Partnership Features:

Agenus has an exclusive option to develop undisclosed targets and option to co-promote in the U.S.

The Details:

  • Agenus granted BMS exclusive, worldwide rights to develop and commercialize AGEN-1777 and an undisclosed target as immuno-oncology therapies, including non-small cell lung cancer (NSCLC).
  • Agenus will initiate the IND application for AGEN-1777.
  • BMS will be responsible for all further development and commercialization.
  • Agenus has an exclusive option to develop undisclosed targets and will have an option to co-promote in the U.S.
  • Agenus will receive $200M up front and is eligible to receive up to $1.36B in milestones, plus tiered double-digit royalties.

Last Month:

The Deal of the Month for April 2021 was the CRISPR – Vertex deal for CTX001. Read about it here.

DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms. We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.

Want data for your analysis? Want us to do it? Subscribers get both.

Schedule your demo of the DealForma database to see how we help you get better reports done faster.

24,551

Deal Profiles

13,873

Funding Rounds

26,380

Company Profiles

16,687

Product Profiles

119K+

Clinical Trials

3,984

Business Developers

Specifically for Biotech, Pharma, Device, and Diagnostics

Get more done.

Stop cleaning data or getting lost in legacy databases. We built DealForma to help you be better and faster at business research. Schedule your customized demo to see how DealForma helps you impress your boss and sign-off early.

More Research by DealForma

Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia

CRISPR Therapeutics and Vertex Pharmaceuticals amended their 2015 deal to develop and commercialize gene editing therapies. This expansion is for Phase I/II CTX001 for severe sickle cell diseases and transfusion-dependent beta-thalassemia. CRISPR will receive $900M up front, up to $200M in milestones upon the first regulatory approval, and a cost/profit split of 40%.

Top Biopharma Deal March 2021: Debiopharm – Merck KGaA for Xevinapant for head and neck cancer

Top Biopharma Deal March 2021: Debiopharm – Merck KGaA for Xevinapant for head and neck cancer

Debiopharm granted Merck exclusive, worldwide rights to develop and commercialize Xevinapant in Phase III for advanced squamous cell carcinoma of the head and neck. Debiopharm will receive EUR188M ($227M) up front and is eligible for up to EUR710M ($856M) in milestones, plus royalties. This was the largest upfront cash and equity for a partnership signed in March 2021.

Biotech and Pharma Deals in 2020

Biotech and Pharma Deals in 2020

Biotech and pharma deals in 2020 soared to an all-time high of 1,154 signed deals with $146.3 billion in total value, defying expectations that the global Covid-19 pandemic would hamper dealmaking. Global healthcare and life sciences R&D partnership activity was up 23 percent over 2019 and total deal values rose 31 percent from the previous year, driven in part by advances in technological and molecular understandings of disease pathways, and a drive toward targeted precision medicines.

Biotech and Pharma M&A in 2020

Biotech and Pharma M&A in 2020

Biotech and pharma M&A total deal values slumped in 2020, despite an active year in life sciences dealmaking, with no big standout biopharma deals until late in the second half of the year. We look at the extensive DealForma database to see how life sciences M&A activity shaped up in 2020 in more detail.

Life Sciences M&A Tops $240 Billion in 2019

Life Sciences M&A Tops $240 Billion in 2019

This article is a sample from the DealForma Annual Deal Trends Report provided to database subscribers. Data for this analysis was compiled using the DealForma biopharma deals database. We applied initial filters for mergers and acquisitions, therapeutic areas, asset...

Cancer Cell Therapy M&A

Cancer Cell Therapy M&A

Over the last three years, there have been eight M&A deals for companies developing advanced first generation and next gen cancer cell therapies. Six of them have been completed to date.

You met on Zoom. Now it's Deal Time.

With thousands of company profiles and a decade of deals specifically in biopharma and medtech, you'll take the guesswork out of deal comps. Schedule your customized demo to see how DealForma helps you win that term sheet with better data.